Harmony Biosciences company information, Employees & Contact Information

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance Investing News Network

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress Yahoo Finance

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series FinancialContent

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference Investing News Network

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 Business Wire

Harmony Biosciences CEO to Present at J.P. Morgan's Prestigious Healthcare Conference 2025 Stock Titan

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome Yahoo Finance

HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024 PR Newswire

HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS PR Newswire

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome Business Wire

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation Business Wire

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025 Business Wire

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts Business Wire

HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY PR Newswire

HARMONY BIOSCIENCES ANNOUNCES TOPLINE DATA FROM PHASE 3 INTUNE STUDY EVALUATING PITOLISANT IN PATIENTS WITH IDIOPATHIC HYPERSOMNIA PR Newswire

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT IN PRADER-WILLI SYNDROME PR Newswire

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES PR Newswire

HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETING PR Newswire

HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY PR Newswire

HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST PR Newswire

Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets PR Newswire

HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME PR Newswire

HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLISANT) PR Newswire

HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY PR Newswire

Harmony Biosciences Announces Closing Of Its Upsized Initial Public Offering And Exercise In Full Of Underwriters' Option To Purchase Additional Shares PR Newswire

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering PR Newswire

Harmony Biosciences And Blackstone Enter Into Strategic Financing Collaboration PR Newswire

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC. PR Newswire

HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION PR Newswire

Harmony Biosciences Appoints Sandip Kapadia as Chief Financial Officer PR Newswire

Harmony Biosciences Acquires Asset With Novel Mechanism Of Action For The Potential Treatment Of Narcolepsy And Other Rare Neurological Diseases PR Newswire

Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy PR Newswire

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference FinancialContent

Harmony Biosciences Announces Date Of Second Quarter 2021 Financial Results pottsmerc.com

Harmony Biosciences Announces Applications for 2021 Patients At The Heart Grant Program Open June 9 Delco Times

Harmony Biosciences to Participate in Three Investor Conferences in June Daily Local

Harmony Biosciences Secures $200 Million Debt Facility PR Newswire

Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy Delco Times